Clinical trial
Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for…
NCT00243854 · Indiana University School of Medicine, Other · Completed
Key facts
| NCT number | NCT00243854 |
|---|---|
| Title | Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer |
| Official title | Pilot Study Using Neoadjuvant Chemo-Radiotherapy and EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer |
| Lead sponsor | Indiana University School of Medicine, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | Tarceva |
| Enrollment | 8 |
| Start date | Nov 1, 2005 |
| Primary completion | Aug 1, 2010 |
| Completion | Oct 1, 2011 |
| First posted | Oct 25, 2005 |
| Last update posted | Mar 18, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: